Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIS OXYS-I trial of hepatic arterial infusion versus intravenous oxaliplatin in liver-dominant malignancies
NL-OMON61698Phase 2Not yet recruiting
- Sponsor
- Erasmus MC
- Start
- Oct 2026
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of oxaliplatin in colorectal cancer liver metastasis (CRLM) and intrahepatic cholangiocarcinoma (ICC) (3 arms), sponsored by Erasmus MC. Primary endpoint: Dose-corrected difference in intra-tumoral total platinum concentration. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
oxaliplatin
03
Conditions
colorectal cancer liver metastasis (CRLM)intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NL-OMON61698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61698.